Immune Design Corp. (NASDAQ:IMDZ) major shareholder Leo Guthart acquired 2,439,000 shares of the stock in a transaction dated Friday, October 27th. The stock was bought at an average price of $4.10 per share, for a total transaction of $9,999,900.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Leo Guthart also recently made the following trade(s):

  • On Tuesday, October 24th, Leo Guthart acquired 60,000 shares of Immune Design Corp. stock. The stock was bought at an average price of $4.65 per share, for a total transaction of $279,000.00.
  • On Thursday, October 19th, Leo Guthart acquired 10,000 shares of Immune Design Corp. stock. The stock was bought at an average price of $6.09 per share, for a total transaction of $60,900.00.
  • On Monday, September 18th, Leo Guthart acquired 10,000 shares of Immune Design Corp. stock. The stock was bought at an average price of $9.70 per share, for a total transaction of $97,000.00.

Immune Design Corp. (IMDZ) opened at 4.95 on Wednesday. The company has a 50-day moving average price of $8.83 and a 200 day moving average price of $8.49. The company’s market capitalization is $126.81 million. Immune Design Corp. has a 12 month low of $3.78 and a 12 month high of $13.05.

Immune Design Corp. (NASDAQ:IMDZ) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. The business had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.50 million. On average, equities research analysts forecast that Immune Design Corp. will post ($2.29) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Immune Design Corp. (IMDZ) Major Shareholder Leo Guthart Acquires 2,439,000 Shares” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://theolympiareport.com/2017/11/01/immune-design-corp-imdz-major-shareholder-leo-guthart-acquires-2439000-shares.html.

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its position in shares of Immune Design Corp. by 170.0% during the 1st quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after buying an additional 70,351 shares during the last quarter. Nationwide Fund Advisors lifted its position in shares of Immune Design Corp. by 1,198.0% during the 2nd quarter. Nationwide Fund Advisors now owns 137,709 shares of the biotechnology company’s stock worth $1,343,000 after buying an additional 127,100 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of Immune Design Corp. by 2.1% during the 2nd quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock worth $19,281,000 after buying an additional 40,010 shares during the last quarter. Bain Capital Public Equity Management LLC lifted its position in shares of Immune Design Corp. by 393.1% during the 2nd quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock worth $3,797,000 after buying an additional 310,433 shares during the last quarter. Finally, Numeric Investors LLC bought a new stake in shares of Immune Design Corp. during the 2nd quarter worth $1,641,000. Institutional investors and hedge funds own 51.44% of the company’s stock.

Several brokerages have recently issued reports on IMDZ. BidaskClub downgraded shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 5th. Royal Bank Of Canada began coverage on shares of Immune Design Corp. in a research note on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price objective on the stock. ValuEngine upgraded shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Tuesday, July 18th. Finally, Wells Fargo & Company downgraded shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $29.00 to $10.00 in a research note on Tuesday, October 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Immune Design Corp. currently has a consensus rating of “Buy” and an average price target of $14.75.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.